ACADIA Pharmaceuticals (MEX:ACAD) Institutional Ownership: 43.37% (As of Jul. 10, 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN460.00
GF Value MXN439.10
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Institutional Ownership?

ACADIA Pharmaceuticals MEX:ACAD -0.11% 73 Institutional Ownership is 43.37% as of Jul. 10, 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN439.10 (Fairly Valued). The stock has 10 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ACADIA Pharmaceuticals's institutional ownership is 43.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ACADIA Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ACADIA Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 63.05%.

ACADIA Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Institutional Ownership Chart

ACADIA Pharmaceuticals Historical Data

The historical data trend for ACADIA Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 44.15 43.55 43.66 44.02 44.90 45.94 45.22 42.91 43.01 43.37
MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 43.37% mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Institutional Ownership of 43.37% as of Jul. 10, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Institutional Ownership too high?
ACADIA Pharmaceuticals' current Institutional Ownership is 43.37%. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Institutional Ownership compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Institutional Ownership of 43.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Institutional Ownership is 43.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN439.10, compared to a current price of MXN460.00 — trading 4.8% above its estimated fair value. The current Institutional Ownership is 43.37%. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Institutional Ownership is 43.37% as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN460.00 is trading 4.8% above its estimated GF Value™ of MXN439.10. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Institutional Ownership: 43.37%
  • GF Value™: MXN439.10 vs. price of MXN460.00 (4.8% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN460.00
Price
MXN439.10
GF Value